Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Evaluation on Seropositive Patients of a Synthetic Vaccine Targeting the HIV Tat Protein

Next Previous
Trial Profile

Evaluation on Seropositive Patients of a Synthetic Vaccine Targeting the HIV Tat Protein

Status: Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 07 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs HIV vaccine (Primary) ; Antiretrovirals
  • Indications HIV-1 infections
  • Focus Therapeutic Use
  • Acronyms EVA TAT
  • Sponsors Biosantech

    • Most Recent Events

    • 15 Mar 2016 According to Biosantech media release, based on the results of this trial, the company will put forward request for a phase III trial (see CTP 700269274) of its anti-HIV vaccine for an extensive evaluation during 2016 and intends to request a MAA for its anti-HIV vaccine in second half of 2018.
    • 15 Mar 2016 According to Biosantech media release, the detailed results of this trial have been published in the scientific journal Retrovirology.
    • 15 Mar 2016 Results published in the Biosantech media release.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top